The Institut Pasteur of Shanghai at the Chinese Academy of Sciences (IPS-CAS) has joined up with London’s MRC Technology to speed China-discovered antibodies into approved drugs. The two entities co-founded the IPS-MRCT Joint Center for Therapeutic Antibodies, which will develop therapeutic antibodies using research done at IPS-CAS. Initially, the new Center will develop antibodies against two targets for an infectious disease and an inflammatory disorder. MRC will add its tech transfer experience to the R&D ability of IPS-CAS.
